Get started

Medical

Why we think SBC Medical Group is set for a rebound soon.Executive Summary: SBC Medical Group Holdings Incorporated has emerged as one of the more compelling names in the post-SPAC public company landscape. Having successfully completed its business combination with Pono Capital Two, Inc. on 17 September 2024, the Japan-based aesthetic medical services provider now trades on Nasdaq under the ticker “SBC”. The SPAC merger valued the company at approximately USD1 billion and provided it with over USD11.7 million in net proceeds; capital that SBC intends to deploy strategically for international growth and asset diversification. Key Investment Pointers: At the heart of SBC Medical’s proposition is its extensive network of franchised and managed clinics in Japan, with forays into Vietnam and the United States. The company offers management services to cosmetic surgery and aesthetic dermatology clinics under the renowned “Shonan Beauty Clinic” brand, covering procurement, HR, customer loyalty, and more. The SPAC listing has provided it with both visibility and liquidity at a time when demand for aesthetic healthcare continues to rise across Asia and globally. The Group’s third-quarter results, covering the period ended 30 September 2024, underscore its operational strength. SBC posted total net revenues of USD53.1 million for Q3, a 12.3% year-on-year increase. Gross profit surged to USD43.2 million, yielding a gross margin of over 81%, reflective of the company’s high-margin service model. While operating income dipped compared to the prior year due to a one-off non-cash stock-based compensation expense of USD12.8 million, net income for the nine-month period still rose to USD40.1 million, a 60% increase compared to the same period in 2023. Its balance sheet tells a story of disciplined financial management and scalability. As of 30 September 2024, SBC held USD137.4 million in cash and cash equivalents, up from USD103 million at the end of 2023. The company also saw a significant reduction in total liabilities from USD115 million to USD91 million, while shareholder equity rose to over USD205 million. These figures point to a solid capital base capable of absorbing strategic investments and macroeconomic volatility. In a move that has drawn considerable market attention, SBC Medical has also initiated a diversification of its corporate treasury into Bitcoin. With the cryptocurrency having rebounded strongly to the USD86,000 level, SBC’s entry appears both timely and calculated. While the exact volume of the acquisition has yet to be disclosed publicly, the Group has indicated that its Bitcoin holdings are part of a broader strategy to preserve purchasing power in a globally inflationary environment and align itself with digital-native investors. The decision places SBC in the company of firms like MicroStrategy and Tesla, which have similarly sought value preservation through Bitcoin. The strategic trifecta of a successful SPAC listing, strong underlying financials, and an asset diversification play into Bitcoin positions SBC Medical favourably in the eyes of institutional investors. With Q4 results expected soon and a bullish cryptocurrency market supporting sentiment, SBC could well be on the cusp of a re-rating by the market. If its fundamentals remain sound—as recent filings suggest—they may indeed ride the same momentum wave currently lifting digital assets and new-age healthcare stocks alike.
NASDAQ:SBCLong
by HASHInvests200
Japan Aesthetics Market Set for Rapid Growth The Japan aesthetics market is on a trajectory of significant expansion, with a projected rise from $4.15 billion in 2025 to $12.97 billion by 2034, driven by a CAGR of 13.50%. This growth is fueled by an aging population, rising demand for non-invasive cosmetic treatments, and increasing consumer interest in aesthetic enhancements. Industry leaders such as Jiyugaoka Clinic, Big Blue株式会社, and Nasdaq-listed SBC Medical are poised to benefit from this flourishing market. Surging Demand for Non-Invasive Aesthetic Treatments One of the most significant trends propelling the Japan aesthetics market is the increasing preference for non-invasive and minimally invasive procedures. Treatments like Botox, dermal fillers, laser therapy, and chemical peels are gaining popularity due to their ability to deliver natural-looking results with minimal downtime. This shift in consumer behaviour, particularly among millennials and middle-aged individuals, is pushing clinics and medical institutions to expand their service offerings. Among the key players, Jiyugaoka Clinic is at the forefront of providing advanced non-surgical aesthetic solutions, leveraging cutting-edge technology to meet the growing demand. Similarly, Big Blue株式会社, a prominent player in Japan’s medical aesthetics industry, is expected to capitalise on the rise of minimally invasive procedures by integrating the latest technology into its service offerings. Aging Population Driving Growth in Anti-Aging Aesthetics Japan’s rapidly aging population is another key driver of market growth. As more individuals seek anti-aging solutions to maintain a youthful appearance and boost self-esteem, the demand for procedures targeting wrinkles, skin laxity, and facial volume loss is accelerating. SBC Medical, a Nasdaq-listed company, is well-positioned to cater to this demand, with a strong presence in Japan’s aesthetic industry and a portfolio of innovative anti-aging treatments. The rising disposable income among Japan’s older demographic is further amplifying demand, leading to increased investment in cosmeceuticals, skin rejuvenation procedures, and cosmetic implants. The trend toward maintaining a youthful look is fostering continuous advancements in facial aesthetics and body contouring solutions, ensuring sustained market growth. Technological Innovations Fueling Market Expansion The aesthetics market in Japan is evolving rapidly due to the integration of state-of-the-art technology in aesthetic treatments. The country’s emphasis on precision, safety, and innovation has led to the development of AI-assisted skin analysis, laser resurfacing, and next-generation cosmetic implants. Jiyugaoka Clinic and Big Blue株式会社 are actively incorporating these advancements, providing highly personalised and effective treatment options to cater to diverse consumer needs. Moreover, SBC Medical’s presence on the Nasdaq market enhances its ability to attract global investors and leverage international expertise in aesthetic dermatology and plastic surgery. With access to cutting-edge research and development, the company is expected to introduce groundbreaking treatments that further strengthen Japan’s position as a leader in the aesthetics industry. A Booming Market with Expanding Opportunities The Japan aesthetics market is poised for exponential growth, driven by increasing awareness, changing beauty standards, and evolving medical advancements. The rise of non-invasive procedures, combined with a strong demand for anti-aging treatments, is creating a lucrative environment for Jiyugaoka Clinic, Big Blue株式会社, and SBC Medical to thrive. As consumer preferences shift towards customised, technology-driven aesthetic solutions, these industry leaders are well-equipped to meet demand, ensuring sustained market dominance in the years to come. Investors and industry stakeholders should closely watch Japan’s aesthetics market, as it continues to set new benchmarks for innovation, safety, and personalised beauty treatments.
NASDAQ:SBCLong
by HASHInvests200
Can Duvakitug Redefine IBD Therapy?Teva Pharmaceuticals, in a groundbreaking collaboration with Sanofi, has unveiled results from the Phase 2b RELIEVE UCCD study that could potentially reshape the landscape of inflammatory bowel disease (IBD) treatment. The study's focus, duvakitug, a novel anti-TL1A monoclonal antibody, has shown remarkable efficacy in managing ulcerative colitis and Crohn's disease, positioning it as a potential best-in-class therapy. With clinical remission and endoscopic response rates significantly outpacing placebo, this development not only challenges existing treatment paradigms but also ignites a spark of hope for millions suffering from these chronic conditions. The implications of duvakitug's success extend beyond immediate patient care; they invite a broader discussion on innovation in the pharmaceutical industry. Teva's strategic pivot towards growth through pioneering drug development efforts underscores a commitment to expanding its portfolio and accelerating access to life-altering treatments. This study's outcomes, showing a favorable safety profile alongside its efficacy, encourage reevaluating how we approach IBD, potentially leading to a future where patients can achieve remission with fewer side effects and less invasive interventions. Moreover, the financial and strategic narrative surrounding Teva's performance in 2024 adds another layer of intrigue. With a notable increase in revenue driven by key products and a focus on both generics and innovative medicines, Teva is not just navigating but also setting the course for future healthcare advancements. The journey of duvakitug from clinical trials to potential Phase 3 trials exemplifies how scientific curiosity, when supported by strategic foresight, can lead to transformative outcomes in medical science, challenging us to imagine a new era in IBD management.
NYSE:TEVALong
by UDIS_View
Technical Analysis on SBC Medical Group (28/01/2025)Neutral Outlook with Key Support at 5.00–5.08 Price Action Analysis SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is currently trading at 5.08 on the day. Over the past week, the stock has shown consolidation within a narrow range of 5.02–5.13, reflecting a balance between buyers and sellers. The 1-hour chart highlights a lack of decisive momentum, with prices hovering near the $5.08 level, suggesting short-term indecision in the market. Immediate Support: The 5.00–5.02 zone has emerged as a critical floor, with the stock rebounding from this level multiple times in recent sessions. A sustained break below $5.00 could signal bearish pressure. Resistance: The upper boundary lies at 5.08–5.13, where the stock has faced selling interest. A close above 5.13 level may retest the previous high in November levels. Trading volume remains subdued, averaging between 33,950–38,980 shares, consistent with consolidation phases. The absence of significant volume spikes indicates limited institutional participation and reinforces the neutral near-term bias. While momentum indicators like the Relative Strength Index (RSI) are not explicitly provided, the sideways price action suggests a neutral RSI reading (near 50), aligning with the lack of overbought or oversold conditions. SBC’s price action reflects a “wait-and-see” approach among market participants. For now, the stock appears anchored near its 5.08 pivot point level. Traders may consider range-bound strategies (e.g., buying near 5.02) until a breakout occurs.
NASDAQ:SBCLong
by dibora_yen91
My 2 cents on the technical movement of this stock..The recent price action of SBC Medical Group Holdings indicates consolidation within the $5.00 to $6.00 range, with $5.00 acting as a strong support level and $6.00 as immediate resistance. The stabilisation at these levels reflects reduced volatility, hinting at a potential accumulation phase. Volume spikes near the $5.00 level further suggest that institutional investors may be positioning themselves, adding to the likelihood of accumulation. This price behaviour indicates a cautious yet potentially promising setup for a breakout. Given the current context, a decisive move above $6.00 with increasing volume would confirm a shift in momentum, opening the possibility for a sustained upward trajectory. Conversely, failure to maintain the $5.00 support could lead to further testing of lower levels, making this range a crucial area to watch. The overall stability around these levels suggests growing interest and positioning ahead of a possible directional move.
NASDAQ:SBCLong
by dibora_yen91
1
BUY Rating: SBC Medical Group – A Compelling Growth StorySBC Medical Group Holdings (NASDAQ: SBC), a leader in end-to-end solutions for aesthetic clinics, has earned a "BUY" rating, reflecting its robust growth trajectory and strategic expansion initiatives. The company’s recent performance and forward-looking plans justify its valuation, presenting an attractive opportunity for investors. Valuation and Market Position Compared with SBC’s current price with a valuation target of $11, underscores its growth potential. Despite facing challenges like fluctuating exchange rates and integration costs from recent acquisitions, the company’s fundamentals remain strong. SBC’s market capitalisation stands at $697 million, supported by an annual revenue estimate of $217 million for 2024, reflecting a year-over-year growth of 12%. While SBC operates in the competitive medical aesthetics space, its comprehensive suite of consulting, marketing, and equipment leasing services distinguishes it from peers. The company’s ability to generate steady revenue and expand profit margins highlights its efficiency in leveraging its unique business model. International Expansion Driving Growth A pivotal driver of SBC's growth is its strategic acquisition of Aesthetic Healthcare Holdings (AHH) in Singapore. AHH operates 21 outlets under established brands like SkinGo! and The Chelsea Clinics. Singapore's business-friendly regulatory environment, strong economic growth, and status as a regional hub make it an ideal base for SBC’s expansion into Southeast Asia. Singapore’s GDP growth and high levels of U.S. foreign direct investment further validate SBC’s choice to focus on the region. This acquisition not only accelerates SBC's regional footprint but also positions the company to capitalise on the growing demand for aesthetic services across Asia. Financial Highlights SBC’s Q3 2024 revenue reached $53.1 million, a 12.3% year-over-year increase, with gross profit rising to $43.2 million and margins improving to 81.5% from 70.9% in the prior year. This growth was driven by a shift toward higher-margin revenue streams, including royalty income (29.6% of revenue) and procurement services (33.1%). The company’s decision to discontinue its lower-margin management services business has further enhanced its profitability. Net income for the quarter was $2.8 million, or $0.03 per share, with strong contributions from franchisee expansion and increased demand for aesthetic treatments. Financial Flexibility SBC's financial position is robust, with $137.4 million in cash and equivalents and less than $15 million in long-term debt as of Q3 2024. This financial flexibility enables the company to fund its growth strategies, including further acquisitions and geographic expansion. Strategic Initiatives Beyond its international expansion, SBC has entered partnerships to enhance customer loyalty and corporate wellness offerings. Its alliance with MEDIROM Healthcare in Japan integrates the loyalty programs of both companies, providing access to over 4 million members. SBC also launched SBC Wellness to offer corporate clients improved employee benefits, tapping into the growing demand for wellness services. Growth Catalysts The rising global acceptance of aesthetic medicine, coupled with SBC’s established expertise in high-demand procedures such as liposuction, breast augmentation, and eyelid surgery, positions the company for continued growth. With low market penetration for these services in Japan (estimated at 10%), there is significant upside as demand grows among younger and middle-aged demographics. Risks and Outlook While SBC faces risks such as foreign exchange fluctuations and potential challenges in integrating new acquisitions, its strong balance sheet and strategic focus mitigate these concerns. As the company continues to execute its growth initiatives, share price appreciation and valuation multiple expansion are likely. Conclusion SBC Medical Group Holdings presents a compelling investment opportunity, with a clear path to growth through strategic international expansion, enhanced profitability, and innovative partnerships. Its current valuation offers an attractive entry point for investors seeking exposure to the growing medical aesthetics sector. With strong financials and a proven business model, SBC is well-positioned to deliver long-term shareholder value.
NASDAQ:SBCLong
by HASHInvests200
Vijaya Diagnostics: Rukega Nahi SaalaPrice is at ATH. You can tell this in strong bullish trend even at first glance. Trend is very strong even if you buy at current ATH 1250 and hold, it can be decent swing trade. Of course price will make a higher swing low. Maybe best range will be around 1070-1085. Trend direction - Bullish Confirmed. Trade direction - Bullish confirmed aligned with long term trend. Entry : 1070-1085. SL : 1035 (book half here) Final SL: 1000 (Exit completely) Target: Current ATH 1250. Risk Reward: 1:5 If you can just wait for optimal entry, you reduce your SL risk significantly. These are types of trades where chart actually invites you to enter, should be never avoided. At least enter with 10qty. You never know compounding effect. This is what I call high quality trade. - Clear Trend established with no confusion, even in bearish market - No sign of exhaustion
NSE:VIJAYALong
by vkfinserv
Healthcare Sector Poised For A 7% to 15% Rally Into Early 2025My continued research to help traders shows the US Healthcare and Biotech sectors are poised for a very large rally phase into early 2025. Particularly, XLV and XBI seem uniquely setup to rally more than 9-10% over the next 60 to 90+ days. This video explains how I use my Adaptive Dynamic Learning Predictive Modeling system to find opportunities other people miss. Using technology, predictive modeling, and inference engines like this is one advantage I have because I can build any type of technology or system I like - and use it on any symbol or interval I like. Now is the time to prepare for the big moves headed into 2025. Follow my research if you want to target the biggest price swings in the markets. Get some. #trading #research #investing #tradingalgos #tradingsignals #cycles #fibonacci #elliotwave #modelingsystems #stocks #bitcoin #btcusd #cryptos #spy #es #nq #gold
AMEX:XLVLong
by BradMatheny
NASDAQ: SBC, Empowering the Growth of Aesthetic MedicalSBC Medical Group Holdings (NASDAQ: SBC) is making waves in the aesthetic medicine industry with its dynamic growth strategy and robust franchise model. Analysts at Zacks have set a target price of $15.40, reflecting confidence in SBC's ability to scale its operations and expand internationally. With a current share price of $6.80 (as of November 2024), the company presents a compelling case for investors seeking growth in an underpenetrated market. Dominance in Japan’s Growing Market SBC operates the largest network of franchised clinics in Japan, with 220 locations under various brands, capturing an estimated 31% market share. Despite its leadership, the Japanese aesthetic medicine market remains relatively untapped, with just 10% penetration. The company treated 3.9 million patients in 2023, a 26% increase from 2021, highlighting the growing demand driven by social media and demographic trends. Comprehensive Solutions and Strong Financials SBC's franchisees benefit from a comprehensive suite of services, including administrative support, marketing, procurement, and technology integration. These offerings enable clinics to focus on high-quality, affordable patient care while expanding their service portfolios. The company’s financial performance reflects its growth momentum, with revenue reaching $193 million in 2023, up 10% year-over-year. A 5-year revenue CAGR of 24% underscores the scalability of its model, supported by a strong EBITDA margin of 42.5% and a robust cash position of $103.7 million. Global Expansion Strategy SBC’s international operations in Vietnam and California signal the early stages of a broader global strategy. The clinics cater to rising demand for popular treatments like liposuction and eyelid surgery, aligning with global trends in non-invasive and surgical procedures. With the global aesthetic medicine market projected to grow from $59.8 billion in 2024 to $81.7 billion by 2032, SBC is well-positioned to capture a significant share. Outlook and Investor Potential The $15.40 target price reflects optimism about SBC’s continued network expansion and revenue growth. While challenges like foreign exchange risks and competitive pressures persist, the company’s innovative approach and financial discipline mitigate these risks. SBC Medical Group stands out as a growth-oriented player in a burgeoning industry. With its proven franchise model and strategic vision, the company offers investors an attractive opportunity to tap into the expanding global aesthetic medicine market.
NASDAQ:SBCLong
by HASHInvests200
MPW at these levels look to be a 20%+ gain within 6-12 monthsI have traded this stock for awhile now and going in and out of it can make you some decent gains. You can see on this chart the upside and downside of it. It has been hit recently because of the default by one of their big tenants. However, this is a fundamentally strong business that will come through that and start to see better results, especially in an interest rate declining environment. I look at this as a minimum 20% upside play in the next 3-6months based on previous timelines, and you could see this run depending on how they navigate coming around the loss of that client. I started a position in the sub $4 range and will look to add to it on any dips due to market dynamics.
NYSE:MPWLong
by jasonbc
Baxter International | BAX | Long at $35.00Baxter International NYSE:BAX , a company that primarily focuses on products to treat kidney disease and other chronic and acute medical conditions, is another name that had a very rough time through 2022 and into 2024. However, the company's projected earnings and cash flow are expected to grow from 2024 through 2027 and it currently has a 3.35% dividend. Interest rates being lowered soon will help these projections. From a technical analysis perspective, my selected simple moving average is working its way down to recapture the price for a likely reversal in the next year or two (unless company fundamentals change). The recent low in June 2024 was higher than the previous low in October 2023 (higher lows) indicating a high chance of future price improvement - but nothing is guaranteed. At $35.00, it is currently in a personal buy zone. Target #1 - $40.00 Target #2 - $48.00 Target #3 - $51.50 Target #4 - $65.00 Target #5 - $77.00 (very long-term...)
NYSE:BAXLong
by WorthlessViews
A promising drug for immunotherapy of solid tumorsKey arguments in support of the idea ▪ Initial clinical data for CLN-619 are pending. Investment thesis Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of cancer. On 1 June, Cullinan Therapeutics will present data from a Phase I clinical trial of its CLN-619 drug. The results of early-phase studies will determine the potential of the experimental drug CLN-619 for immunotherapy of solid tumors and hematological malignancies. At the upcoming 2024 ASCO Annual Meeting, the Company will present new data from the Phase 1 study (NCT05117476) of CLN619 in patients with solid tumors. The monoclonal antibody CLN619 binds to receptors on the tumor surface and increases theproduction of proteins recognized by immune system cells that attack the tumor. Cullinan Therapeutics is exploring the therapeutic potential of CLN-619 as a monotherapy for cancers and in combination with KEYTRUDA (pembrolizumab). The study results announced last week indicated a favorable safety profile for the drug and we expect the presentation to confirm its therapeutic potential and the ability to progress into further phases of the study. In addition, a second Phase 1 study in patients with multiple myeloma will be initiated in the coming months. Cullinan Therapeutics has a diversified pipeline of immunotherapy drugs with various mechanisms, including a latestage anti-tumor drug. One of the lead candidates, developed jointly with Taiho Oncology, is zipalertinib for the treatment of NSCLC. The Company continues to actively enroll patients in its Phase 3 study designed to evaluate the efficacy of zipalertinib as a first-line therapy for NSCLC. In addition, in the second half of the year, Cullinan Therapeutics will present the first results from the Phase 1 clinical trials on its CLN-049 and CLN-418 candidates for the immunotherapy of recurrent hematologic oncohematologic diseases and various types of solid tumors, respectively. We set a Buy rating on CGEM stock with a 2-month price target of $29.5. A stop loss order is recommended at $20.5.
NASDAQ:CGEMLong
by FreedomHolding
PILL 3x Leverage Medical/ Pharma ETF for swing LONGAMEX:PILL On the 4H Chart, current market price is sitting on the support of order blocks and the EMA200, while in an uptend from a double bottom in the sprint. It is moving into the high volume area of the voluxme profile. For the swing trade, the stop loss is $0.10 below the EMA200 while the targets are marked based on a combination of the horizontal resistances of prior swing pivots along with sell order blocks and the structure of the volume profile. Accordingly, this trade risks $0.60 for about $ 4 to $ 5 of upside making for an excellent swing setup especially since healthcare, medical and pharmacueticals are known to be recession resilient and ETFs are inherently diversified making leveraging a risk probably worth taking.
AMEX:PILLLong
by AwesomeAvani
LABU / LABD Medical Leveraged ETFs Flip Strategy.LABU is shown here on a 2H time frame. I am holding 500 shares having bought November 14th on golden cross of fast and slow hull moving averages. The unrealized gain is 50%. Here, I determine that I should en bloc or in increments close the position. First, on the dual time RSI indicator of Chris Moody, the RSI is now over 60 and approaching 65. Price pivoted when RSI was in this range as shown by the red down arrows on the chart. A fibonacci analysis is that the LABU downtrend of early September to late October has now retraced in the range of 50% with the mid levels shown on the chart from the drawing tool. Because of these two considerations, I believe that I should bank the 50% profit in less than 3 weeks and perhaps take a position in the inverse ETF LABD. I will do this on a 15 minute time frame, take off one fifth of the position daily at the high of day as determined by an alert for the faster Hull Moving Average doing down instead of upsloping. At the same time on the LABD 15 minute chart I will buy a corresponding position at the low of day again using an alert. By the end of the five days, the LABU position will be closed and the profits redeployed into LABD. When LABD retraces 505 of its downtrend and RSI rises above 60, I will consider fading the position and retaking a position in LABU. thus toggling positions in the inverse ETFs as analysis and indicators dictate.
AMEX:LABULong
by AwesomeAvani
1
Baxter Inc. (BAX) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company Baxter International Inc. (BAX). Baxter International Inc. is an American multinational healthcare company. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 41.98 USD. According to experts, your stop-loss order should be placed at 37.35 USD if you decide to enter this position. U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co and Carlyle Group, have also expressed interest in the Baxter business, the sources said. Other bidders could still emerge, they added. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
NYSE:BAXLong
by legacyFXofficial
Fresenius (FRE.de) bearish scenario:The technical figure Channel Up can be found in the daily chart in the German company Fresenius SE & Co. KGaA (FRE.de). Fresenius SE & Co. KGaA is a European multinational healthcare company. It provides products and services for dialysis in hospitals and inpatient and outpatient medical care. It is involved in hospital management and in engineering and services for medical centers and other healthcare facilities. Channel Up broke through the support line on 24/02/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 15 days towards 24.00 EUR. According to experts, your stop-loss order should be placed at 29.710 EUR if you decide to enter this position. Fresenius SE is exploring steps to relinquish control of its dialysis subsidiary as Elliott Investment Management puts pressure on the German healthcare company to simplify its business. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:FREShort
by legacyFXofficial
GMVD | A Low Float Monster | Oversold G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.
GLong
by DivergenceSeeker
2
ATIP | I Spy An Insider Buy | LONGATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity assessment, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in progressive therapies; and sports medicine, including onsite sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI Physical Therapy name. As of December 31, 2021, it had 910 owned and 20 managed clinics. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.
ALong
by DivergenceSeeker
LABU target price based on pitchfork analysisTwo pitchfork lines (one with dashed lines and one with sold lines) neatly matched their bottom lines. The price (approximately) reached that level 5 times. Further, the solid's middle red line matches pretty well the dashed pitchfork top lines. All these makes for a more confident prediction(s). The first is that the price will reach above 14 (the top dashed line), as marked. That would be above 75% increase from current price. At that point the price may or may not temporarily fall back after which I expect to continue up reaching above 22 (the marked top solid pitchfork line). That's over 175% profit. I have been long on LABU since 6.47 (as posted elsewhere).
AMEX:LABULong
by TradersForecast